Fusion Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 94.9 million compared to USD 87.61 million a year ago. Basic loss per share from continuing operations was USD 1.45 compared to USD 2 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.4 USD | +0.02% | -0.44% | +122.63% |
07/05 | Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
16/04 | TD Cowen Downgrades Fusion Pharmaceuticals to Hold | MT |
EPS Revisions
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023